We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
US's Largest Stocks May Be Stretching Their Valuation Multiples Too Thin
Read MoreHide Full Article
Microsoft (MSFT - Free Report) and Apple (AAPL - Free Report) , the US’s largest publicly traded companies, making up 10% of the S&P 500, reported powerful quarterly results this week. These trillion dollar companies are undoubtedly market moving stocks, yet the markets have traded down roughly 2.5% off its highs last week.
Investors may be beginning to pull profits off the table with the coronavirus seeming to be a good enough catalyst.
The S&P 500 is trading right off its highest forward P/E valuation since the dotcom bubble. The 2019 equity market was primarily driven by a valuation push as investors priced in future growth. If forward guidance doesn’t match expectations, there could be a pullback in the equities, especially those that have seen significant valuation multiple growth.
In this video I will discuss whether AAPL and MSFT have stretched their valuation multiples too far or if these stocks have more growth to be priced in.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
US's Largest Stocks May Be Stretching Their Valuation Multiples Too Thin
Microsoft (MSFT - Free Report) and Apple (AAPL - Free Report) , the US’s largest publicly traded companies, making up 10% of the S&P 500, reported powerful quarterly results this week. These trillion dollar companies are undoubtedly market moving stocks, yet the markets have traded down roughly 2.5% off its highs last week.
Investors may be beginning to pull profits off the table with the coronavirus seeming to be a good enough catalyst.
The S&P 500 is trading right off its highest forward P/E valuation since the dotcom bubble. The 2019 equity market was primarily driven by a valuation push as investors priced in future growth. If forward guidance doesn’t match expectations, there could be a pullback in the equities, especially those that have seen significant valuation multiple growth.
In this video I will discuss whether AAPL and MSFT have stretched their valuation multiples too far or if these stocks have more growth to be priced in.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>